InstitutionMD Anderson
DepartmentClinical Cancer Prevention
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Brown P. Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved. Oncologist. 2016 Jan; 21(1):4-6. PMID: 26675741; PMCID: PMC4709217.
      Citations: 1     Fields:    Translation:HumansCells
    2. Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH. Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest. 2015 Jul 01; 125(7):2707-20. PMID: 26075823; PMCID: PMC4563671.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    3. Haricharan S, Brown P. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):E3216-25. PMID: 26063617; PMCID: PMC4485113.
      Citations: 31     Fields:    Translation:HumansCells
    4. Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014 Dec; 15(13):e625-e634. PMID: 25456381; PMCID: PMC4413447.
      Citations: 90     Fields:    Translation:Humans
    5. Rechoum Y, Rovito D, Iacopetta D, Barone I, Weigel NL, O'Malley BW, Brown PH, Fuqua SA, And? S. AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85. PMID: 25178514; PMCID: PMC4337991.
      Citations: 40     Fields:    Translation:HumansCells
    6. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep; 7(9):886-95. PMID: 24961880; PMCID: PMC4408535.
      Citations: 23     Fields:    Translation:Humans
    7. Brown P. Prevention: targeted therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol. 2014 Mar; 11(3):127-8. PMID: 24535168.
      Citations: 5     Fields:    Translation:Humans
    8. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG, Wade JL, Lippman SM. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10; 31(23):2942-62. PMID: 23835710.
      Citations: 116     Fields:    Translation:Humans
    9. Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJ. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013 Jul; 6(7):646-55. PMID: 23682075; PMCID: PMC3707304.
      Citations: 10     Fields:    Translation:Humans
    10. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54. PMID: 22827973; PMCID: PMC3816771.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    11. Mohebati A, Knutson A, Zhou XK, Smith JJ, Brown PH, Dannenberg AJ, Szabo E. A web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokers. Contemp Clin Trials. 2012 Sep; 33(5):942-8. PMID: 22771576; PMCID: PMC3460548.
      Citations: 7     Fields:    Translation:Humans
    12. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor ? in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012 Sep; 9(9):530-8. PMID: 22710573; PMCID: PMC3745216.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    13. Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. A SNP in steroid receptor coactivator-1 disrupts a GSK3? phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol. 2012 Feb; 26(2):220-7. PMID: 22174377; PMCID: PMC3275159.
      Citations: 10     Fields:    Translation:HumansCells
    14. Rodenberg JM, Bissonnette RP, Brown PH, Mancini MA, Uray IP. Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor ?-dependent mechanism. Mol Pharmacol. 2012 Feb; 81(2):228-38. PMID: 22053058; PMCID: PMC3263950.
      Citations: 7     Fields:    Translation:HumansCells
    15. Dearth RK, Kuiatse I, Wang YF, Liao L, Hilsenbeck SG, Brown PH, Xu J, Lee AV. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377. PMID: 21867536; PMCID: PMC3189189.
      Citations: 5     Fields:    Translation:AnimalsCells
    16. Howe LR, Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila). 2011 Aug; 4(8):1149-57. PMID: 21816844; PMCID: PMC3171200.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    17. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011 Jul 08; 8(1):11. PMID: 21906370; PMCID: PMC3170272.
      Citations: 49     
    18. Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AV. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73. PMID: 21541704; PMCID: PMC3936881.
      Citations: 23     Fields:    Translation:HumansCells
    19. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503. PMID: 21441069.
      Citations: 77     Fields:    Translation:Humans
    20. Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P, kConFab, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8. PMID: 20921021; PMCID: PMC3003879.
      Citations: 23     Fields:    Translation:Humans
    21. Johnson KA, Brown PH. Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol. 2010 Aug; 37(4):345-58. PMID: 20816505.
      Citations: 24     Fields:    Translation:Humans
    22. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40. PMID: 20569503; PMCID: PMC2917035.
      Citations: 117     Fields:    Translation:HumansCells
    23. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PH. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61. PMID: 19920204; PMCID: PMC2830975.
      Citations: 56     Fields:    Translation:HumansCells
    24. Brown PH, Viner JL, Brewster A, Heckman CJ, Hursting S, Johnson K, Mao JT. Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila). 2009 Nov; 2(11):995-8. PMID: 19892666; PMCID: PMC2830974.
      Citations:    Fields:    Translation:Humans
    25. Rodenberg JM, Brown PH. A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin. Cancer Prev Res (Phila). 2009 Nov; 2(11):915-8. PMID: 19861544.
      Citations: 2     Fields:    Translation:HumansCells
    26. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40. PMID: 19808870; PMCID: PMC2763053.
      Citations: 59     Fields:    Translation:HumansCells
    27. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM, American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 01; 27(19):3235-58. PMID: 19470930; PMCID: PMC2716943.
      Citations: 99     Fields:    Translation:Humans
    28. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Thun M, Senn HJ. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009 May; 10(5):501-7. PMID: 19410194.
      Citations: 292     Fields:    Translation:Humans
    29. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14. PMID: 19241157; PMCID: PMC5921048.
      Citations: 32     Fields:    Translation:HumansCells
    30. Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, Brown PH. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74. PMID: 19174577; PMCID: PMC2995265.
      Citations: 7     Fields:    Translation:Animals
    31. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PH. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13. PMID: 19141783; PMCID: PMC2639315.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    32. Li Y, Brown PH. Prevention of ER-negative breast cancer. Recent Results Cancer Res. 2009; 181:121-34. PMID: 19213564; PMCID: PMC4068124.
      Citations: 11     Fields:    Translation:Humans
    33. Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS, American Society of Clinical Oncology. American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol. 2009 Feb 20; 27(6):986-93. PMID: 19075281; PMCID: PMC2668639.
      Citations: 26     Fields:    Translation:Humans
    34. Speers C, Brown P. Breast cancer prevention using calcium and vitamin D: a bright future? J Natl Cancer Inst. 2008 Nov 19; 100(22):1562-4. PMID: 19001596; PMCID: PMC3299212.
      Citations: 3     Fields:    Translation:Humans
    35. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM, CEBP Senior Editors and CaPR Deputy and Senior Editors. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5. PMID: 19138984.
      Citations:    Fields:    Translation:Humans
    36. Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM, CEBP Senior Editors and CaPR Deputy and Senior Editors. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5. PMID: 18990728.
      Citations: 1     Fields:    Translation:Humans
    37. Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D. The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila). 2008 Aug; 1(3):161-6. PMID: 19138951; PMCID: PMC2758098.
      Citations: 11     Fields:    Translation:HumansAnimals
    38. Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LR. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila). 2008 Aug; 1(3):208-14. PMID: 19138958; PMCID: PMC2612594.
      Citations: 11     Fields:    Translation:AnimalsCells
    39. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PH. Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55. PMID: 19138935; PMCID: PMC2577387.
      Citations: 13     Fields:    Translation:AnimalsCells
    40. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer. 2008 Apr 22; 98(8):1380-8. PMID: 18362934; PMCID: PMC2361704.
      Citations: 18     Fields:    Translation:AnimalsCells
    41. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31. PMID: 17947490.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    42. Brown PH. Chemoprevention clinical trials: it is time to turn success into progress. Cancer Epidemiol Biomarkers Prev. 2007 Aug; 16(8):1531-2. PMID: 17684123.
      Citations: 1     Fields:    Translation:Humans
    43. DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PH. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol. 2007 Oct 15; 277(1-2):13-25. PMID: 17825481.
      Citations: 22     Fields:    Translation:HumansCells
    44. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2008 Jan 10; 27(3):366-77. PMID: 17637753.
      Citations: 58     Fields:    Translation:HumansCells
    45. Li Y, Brown PH. Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev. 2007 Jun; 16(3):203-15. PMID: 17415091.
      Citations: 8     Fields:    Translation:Humans
    46. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76. PMID: 17493263; PMCID: PMC1929138.
      Citations: 617     Fields:    Translation:HumansAnimals
    47. Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 2007; 9(1):R12. PMID: 17257424; PMCID: PMC1851398.
      Citations: 29     Fields:    Translation:Animals
    48. Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18. PMID: 17178900.
      Citations: 23     Fields:    Translation:HumansAnimals
    49. Uray IP, Brown PH. Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs. 2006 Dec; 15(12):1583-600. PMID: 17107283.
      Citations: 7     Fields:    Translation:HumansAnimals
    50. Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TC. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol. 2007 Feb 15; 73(4):481-90. PMID: 17126817; PMCID: PMC1829171.
      Citations: 6     Fields:    Translation:HumansCells
    51. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5902-9. PMID: 17020999.
      Citations: 28     Fields:    Translation:HumansAnimals
    52. Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 2006 May 15; 66(10):5304-13. PMID: 16707456.
      Citations: 39     Fields:    Translation:HumansCells
    53. Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PH. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006 Jul 15; 295(2):589-603. PMID: 16678816.
      Citations: 21     Fields:    Translation:Animals
    54. Seo HS, DeNardo DG, Jacquot Y, Vidal DS, Zambrana CR, Leclercq G, Brown PH, La?os I. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat. 2006 Sep; 99(2):121-34. PMID: 16541309.
      Citations: 42     Fields:    Translation:HumansCells
    55. Jang KS, Han HX, Paik SS, Brown PH, Kong G. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 2006 Dec 08; 244(2):203-10. PMID: 16469432.
      Citations: 12     Fields:    Translation:Humans
    56. Wu K, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH, DuPr? E. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat. 2006 Mar; 96(2):147-57. PMID: 16273314.
      Citations: 17     Fields:    Translation:HumansCells
    57. Lu C, Shen Q, Kim H, Hilsenbeck S, Brown PH, DuPr? E. cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24. PMID: 16027729.
      Citations: 28     Fields:    Translation:HumansCells
    58. Shen Q, Brown PH. Transgenic mouse models for the prevention of breast cancer. Mutat Res. 2005 Aug 25; 576(1-2):93-110. PMID: 15888345.
      Citations: 10     Fields:    Translation:AnimalsCells
    59. Brown PH, Rashid A. Cancer prevention: the importance of accurate risk assessment. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1357-8. PMID: 15941935.
      Citations:    Fields:    Translation:Humans
    60. Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P. Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res. 2005 Apr 15; 65(8):3493-6. PMID: 15833886.
      Citations: 20     Fields:    Translation:Animals
    61. Kalidas M, Brown P. Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer. 2005 Apr; 6(1):27-37. PMID: 15899070.
      Citations: 4     Fields:    Translation:Humans
    62. Brown P. Risk assessment: controversies and management of moderate- to high-risk individuals. Breast J. 2005 Mar-Apr; 11 Suppl 1:S11-9. PMID: 15725110.
      Citations: 2     Fields:    Translation:Humans
    63. Kalidas M, Hilsenbeck S, Brown P. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3. PMID: 15572750.
      Citations: 1     Fields:    Translation:Humans
    64. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78. PMID: 15514030.
      Citations: 37     Fields:    Translation:HumansCells
    65. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PH. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene. 2004 Oct 28; 23(50):8238-46. PMID: 15378019.
      Citations: 31     Fields:    Translation:HumansCells
    66. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6(6):240-5. PMID: 15535853; PMCID: PMC1064085.
      Citations: 88     Fields:    Translation:Humans
    67. Campiglio M, Normanno N, M?nard S. Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2004 May 05; 96(9):715; author reply 715-6. PMID: 15126613.
      Citations: 4     Fields:    Translation:Animals
    68. Kramer R, Brown P. Should tamoxifen be used in breast cancer prevention? Drug Saf. 2004; 27(13):979-89. PMID: 15471505.
      Citations: 3     Fields:    Translation:Humans
    69. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33. PMID: 14679152.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    70. Schiff R, Chamness GC, Brown PH. Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31. PMID: 12927029; PMCID: PMC314430.
      Citations: 8     Fields:    Translation:HumansAnimals
    71. Wu K, Brown P. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst. 2003 Jun 04; 95(11):766-7. PMID: 12783921.
      Citations:    Fields:    Translation:Humans
    72. Ip C, Brown P. Prevention of breast cancer--present reality and future promise. J Mammary Gland Biol Neoplasia. 2003 Jan; 8(1):1-3. PMID: 14587859.
      Citations:    Fields:    Translation:Humans
    73. Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, Green JE. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res. 2002 Dec; 11(6):617-33. PMID: 12509137.
      Citations: 3     Fields:    Translation:AnimalsCells
    74. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80. PMID: 12438218.
      Citations: 55     Fields:    Translation:AnimalsCells
    75. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9. PMID: 12400010.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    76. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW. The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem. 2002 Jul 12; 277(28):25313-22. PMID: 12000762.
      Citations: 22     Fields:    Translation:Cells
    77. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74. PMID: 12010861.
      Citations: 46     Fields:    Translation:Animals
    78. You H, Yu W, Munoz-Medellin D, Brown PH, Sanders BG, Kline K. Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog. 2002 Apr; 33(4):228-36. PMID: 11933076.
      Citations: 5     Fields:    Translation:HumansCells
    79. Yang L, Ostrowski J, Reczek P, Brown P. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene. 2001 Nov 29; 20(55):8025-35. PMID: 11753686.
      Citations: 7     Fields:    Translation:HumansCells
    80. Ludes-Meyers JH, Liu Y, Hilsenbeck SG, Brown PH, Mu?oz-Medellin D. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80. PMID: 11420689.
      Citations: 22     Fields:    Translation:HumansCells
    81. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem. 2001 Jul 27; 276(30):27907-12. PMID: 11353774.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    82. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34. PMID: 11106684.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    83. Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704. PMID: 10999763.
      Citations: 30     Fields:    Translation:Animals
    84. Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast Cancer Res Treat. 2000 Jul; 62(1):1-17. PMID: 10989982.
      Citations: 17     Fields:    Translation:Humans
    85. Lippman SM, Brown PH. Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst. 1999 Nov 03; 91(21):1809-19. PMID: 10547388.
      Citations: 7     Fields:    Translation:Humans
    86. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70. PMID: 10557095.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    87. Yang LM, Tin-U C, Wu K, Brown P. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia. 1999 Oct; 4(4):377-88. PMID: 10705921.
      Citations: 8     Fields:    Translation:HumansAnimals
    88. Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH. Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat. 1999 Aug; 56(3):277-91. PMID: 10573118.
      Citations: 2     Fields:    Translation:HumansCells
    89. Yu W, Simmons-Menchaca M, You H, Brown P, Birrer MJ, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog. 1998 Aug; 22(4):247-57. PMID: 9726817.
      Citations: 5     Fields:    Translation:HumansCells
    90. Osborne CK, Elledge RM, Brown PH, Hilsenbeck SG. BRCA1 in clinical breast cancer. Breast Dis. 1998 Apr; 10(1-2):77-88. PMID: 15687551.
      Citations:    Fields:    
    91. Yang L, Kim HT, Munoz-Medellin D, Reddy P, Brown PH. Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res. 1997 Oct 15; 57(20):4652-61. PMID: 9377582.
      Citations: 10     Fields:    Translation:HumansCells
    92. Smith LM, Birrer MJ, Stampfer MR, Brown PH. Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997 Jul 15; 57(14):3046-54. PMID: 9230221.
      Citations: 10     Fields:    Translation:HumansCells
    93. Zhao B, Yu W, Qian M, Simmons-Menchaca M, Brown P, Birrer MJ, Sanders BG, Kline K. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog. 1997 Jul; 19(3):180-90. PMID: 9254885.
      Citations: 6     Fields:    Translation:HumansCells
    94. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ. 1996 Aug; 7(8):1013-21. PMID: 8853897.
      Citations: 17     Fields:    Translation:AnimalsCells
    95. Kim S, Brown PH, Birrer MJ. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Oncogene. 1996 Mar 07; 12(5):1043-53. PMID: 8649795.
      Citations: 3     Fields:    Translation:AnimalsCells
    96. Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar; 15(3):215-26. PMID: 8597534.
      Citations: 20     Fields:    Translation:HumansCells
    97. Battey JF, Brown PH, Gritz ER, Hong WK, Johnson BE, Karp DD, Mulshine JL, Shaw GL, Shopland DR, Sunday ME, et al. Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. Lung Cancer. 1995 Mar; 12(1-2):91-103. PMID: 7600036.
      Citations:    Fields:    Translation:Humans
    98. Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 1994 Mar; 9(3):791-9. PMID: 8108121.
      Citations: 61     Fields:    Translation:AnimalsCells
    99. Kurie JM, Brown P, Salk E, Scheinberg D, Birrer M, Deutsch P, Dmitrovsky E. Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. Differentiation. 1993 Sep; 54(2):115-22. PMID: 8243888.
      Citations: 3     Fields:    Translation:HumansCells
    100. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 1993 Apr; 8(4):877-86. PMID: 8455942.
      Citations: 78     Fields:    Translation:HumansAnimalsCells
    101. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S. PMID: 8380133.
      Citations: 5     Fields:    Translation:HumansCells
    102. Birrer MJ, Brown PH. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res. 1992 May 01; 52(9 Suppl):2658s-2664s. PMID: 1562996.
      Citations: 6     Fields:    Translation:Humans
    103. Birrer MJ, Alani R, Cuttitta F, Preis LH, Sabich AL, Sanders DA, Siegfried JM, Szabo E, Brown PH. Early events in the neoplastic transformation of respiratory epithelium. J Natl Cancer Inst Monogr. 1992; (13):31-7. PMID: 1389694.
      Citations: 4     Fields:    Translation:Humans
    104. Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJ, et al. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem Suppl. 1992; 16G:183-6. PMID: 1469899.
      Citations:    Fields:    Translation:Humans
    105. Alani R, Brown P, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer MJ, Bin?truy B. The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol. 1991 Dec; 11(12):6286-95. PMID: 1944289; PMCID: PMC361817.
      Citations: 39     Fields:    Translation:AnimalsCells
    106. Szabo E, Preis LH, Brown PH, Birrer MJ. The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. Cell Growth Differ. 1991 Oct; 2(10):475-82. PMID: 1751404.
      Citations: 10     Fields:    Translation:HumansCells
    107. Ponzio NM, Brown PH, Thorbecke GJ. Host-tumor interactions in the SJL lymphoma model. Int Rev Immunol. 1986 Jul; 1(3-4):273-301. PMID: 3334050.
      Citations: 8     Fields:    Translation:Cells
    108. Brown PH, Coico RF, Thorbecke GJ. Proliferative responses of T cells from SJL----F1 and F1----SJL bone marrow chimeras to SJL lymphoma cells. Cell Immunol. 1986 Mar; 98(1):18-27. PMID: 3527449.
      Citations:    Fields:    Translation:AnimalsCells
    109. Brown PH, Thorbecke GJ. Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T cells. J Immunol. 1985 Nov; 135(5):3572-80. PMID: 3900211.
      Citations: 4     Fields:    Translation:AnimalsCells
    110. DeKruyff RH, Brown PH, Thorbecke GJ, Ponzio NM. Characterization of SJL T cell clones responsive to syngeneic lymphoma (RCS): RCS-specific clones are stimulated by activated B cells. J Immunol. 1985 Nov; 135(5):3581-6. PMID: 2413126.
      Citations: 4     Fields:    Translation:AnimalsCells
    111. Brown PH, Mathis D, Cone RE, Jones PP, Ponzio NM, Thorbecke GJ. Properties of reticulum cell sarcomas in SJL/J mice. VIII. Prominent role of RCS cell I-A antigens in the stimulation of syngeneic T cells. Immunogenetics. 1983; 18(4):399-413. PMID: 6226603.
      Citations: 2     Fields:    Translation:AnimalsCells
    112. Phase ib randomized, Double-blinded, Placebo- Controlled, Dose escalation study of polyphenon e in patients with barrett's esophagus. Cancer Prevention Research. 8:1131-1137.
    113. 9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu-transgenic mice. Breast Cancer Research and Treatment. 69:226.
    114. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research. 21:1688-1698.
    115. Development of SJL T cell clones responsive to syngeneic lymphoma (RCS) and activated B cells. Federation Proceedings. 44:3237.
    116. Blockade of AP-1 potentiates endocrine therapy and overcomes resistance. Molecular Cancer Research. 14:470-481.
    117. Long-term effects of inhaled budesonide on screening-detected lung nodules. Annals of Oncology. 26:1025-1030.
    118. Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment. 141:375-384.
    119. Retinoids and rexinoids in cancer prevention. Seminars in Oncology. 43:49-64.
    120. Federation Proceedings. 43.
    121. American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Oncology Practice. 5:196-199.
    122. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    123. Advances in targeted therapy for the prevention of breast cancer. Breast Diseases. 24:309-314.
    124. Identification of proteins associated with the AP-1 transcription factor that are critical for breast cancer growth. Breast Cancer Research and Treatment. 69:234.
    125. Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer. Clinical Cancer Research. 22:5864-5875.
    126. Oncologist. 21:4-6.
    127. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. Journal of Cellular Biochemistry. 50:183-186.
    128. Overexpression of cJun in breast cancer cells inhibits growth and induces cell death. Breast Cancer Research and Treatment. 69:273.
    129. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    130. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II). Breast Diseases. 25:214-216.
    131. Advances in preventive therapy for estrogen-receptor-negative breast cancer. Current Breast Cancer Reports. 6:96-109.
    132. Cancer Prevention, Screening, and Early Detection. 322-359.
    133. Effects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics.
    134. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Breast Diseases. 16:73-74.
    135. Strategies of hormonal prevention. 195-229.
    136. Chemoprevention.
    137. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 7:13106-13121.
    138. AP-1 blockade in vivo suppresses development of mammary tumor im MMTV- erbB2 mice. Cancer Epidemiology, Biomarkers and Prevention. 14.
    139. Animal models for breast cancer prevention research. 497-526.
    140. RXR-selective retinoids function independently of RAR and PPARγ to inhibit breast cell growth. Breast Cancer Research and Treatment. 69:274.
    141. Targeted therapy for breast cancer prevention. Frontiers in Oncology. 3 SEP.
    142. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Research. 76:1942-1953.
    143. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment. 1-14.
    BROWN's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (503)
    Co-Authors (41)
    Similar People (60)
    Same Department Expand Description